Microreviews in Cell and Molecular Biology
An undergraduate science journal
2023

# Cancer stem cell as a promising therapeutic target for cancer therapy

Jazmin Navarro Cisneros
Biology Pre-Med
Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK 74078, USA

**Key Words:**
Stem cell, transcription factors, mesenchymal, stem cell therapy

**The use of cancer stem cells (CSCs) as therapeutic targets for cancer therapy has gained significant attention in recent years. The importance of CSCs lies in their ability to self-renew and differentiate into multiple cell types, leading to tumor initiation, growth, and resistance to therapy. Several articles have discussed the role of CSCs in tumor progression, and the potential therapeutic strategies for targeting CSCs. There are three articles that will be discussed are as follows. The first article "Targeting cancer stem cell pathways for cancer therapy" by Liqun Yang et al. provides an overview of the signaling pathways that regulate CSCs and discusses potential therapeutic strategies for targeting these pathways. The article highlights the latest advances in our understanding of CSC biology and discusses potential new drug targets and treatment strategies, which can guide future research and drug development efforts. The second article "Cancer stem cell: target for anti-cancer therapy" by Carol Tang et al. discusses the importance of targeting CSCs as a promising approach for developing effective cancer therapies. The article highlights the current state of knowledge regarding the signaling pathways and molecular mechanisms that regulate CSCs. And lastly, the third article "Cancer Stem Cells: Implications for Cancer Therapy" by Isidro Sánchez-Garca et al. covers the difficulties in creating efficient CSC-based medicines and underlines the requirement for a deeper comprehension of the molecular processes that control CSCs. While the potential of targeting CSCs for cancer therapy is promising, several challenges still need to be addressed, including the identification and isolation of CSCs, the development of efficient CSC-based medicines, and the containment of good outcomes for cancer patients. Nonetheless, the continued research and development in this field provide hope for the future of cancer therapy.**

## Introduction

In the late 1900's cancer stem cells were first identified in leukemia (Yang). Ever since, the fight to cure cancer has rooted in various directions. One of them is targeting the pathway of cancer stem cells. There are certain types of cancer that can be treated with cancer stem cell therapy. Some of these types of cancers would involve leukemia, lymphoma, and multiple myeloma. A way this treatment would work would be by removing or extracting cancerous cells found in a patient and replacing them with new healthy stem cells to help the patients cells start new. The importance of researching this new treatment is to create new stem cells in a patient's body that can proliferate and differentiate from cancerous cells. Many cancer patients that undergo chemotherapy or radiation

 

therapy in high doses often end up destroying their stem cells. It is crucial to contain these stem cells as they grow and differentiate into different cells the body needs. The stem cell therapies that are available today are mesenchymal stem cells, skin stem cells, brain stem cells, and hematopoietic stem cells. Although these types of stem cell therapies contain metastasis and radiation resistance, researchers are now trying to determine if targeting stem cells pathways can eradicate cell growth in tumors.

**Recent Progress**

In the year 2020, Liqun Yang and colleagues published their research titled "Targeting cancer stem cell pathways for cancer therapy" in the journal Signal Transduction and Targeted Therapy. The article examines the part that cancer stem cells (CSCs) play in the development, growth, and recurrence of tumors (Yang). It gives a summary of the signaling pathways that control CSCs and talks about possible treatment approaches to target these pathways.

This article's relevance and significance stem from the fact that CSCs play a significant role in metastasis, tumor recurrence, and failure of cancer treatments. Developing effective cancer medicines that can destroy the cancer cells responsible for these unfavorable outcomes may be possible by targeting CSCs. Additionally, this essay covers the most recent developments in our comprehension of CSC biology and explains prospective new pharmacological targets and treatment plans that may serve as a direction for upcoming research and drug development initiatives. The article "Cancer stem cell: target for anti-cancer therapy" by Carol Tang et al. was published in the journal The FASEB Journal in 2007. The article discusses the role of cancer stem cells (CSCs) in tumor initiation, progression, and metastasis (Tang). It highlights the importance of targeting CSCs as a promising approach for developing effective cancer therapies, and it provides an overview of the current state of knowledge regarding the signaling pathways and molecular mechanisms that regulate CSCs. The relevance and importance of this article lie in the fact that CSCs are a major contributor to cancer treatment failure, tumor recurrence, and metastasis. Targeting CSCs could provide a promising approach for developing effective cancer therapies that can eradicate the cancer cells responsible for these undesirable outcomes. Moving forward, this article highlights the latest advancements in our comprehension of CSC biology and potential new drug targets and treatment strategies, which can guide future research and drug development efforts. The article's contribution to cancer research and its impact on the development of effective cancer therapies make it an important and relevant publication in the field.

Isidro Sánchez-Garcia et al.'s work titled "Can cancer-stem cell-based therapeutics be put into practice?" was released in the year 2007 in the journal BioEssays. The theoretical underpinnings of employing cancer stem cells (CSCs) as a target for cancer therapy are covered in the article, along with the difficulties in creating efficient CSC-based medicines. It underlines the requirement for a deeper comprehension of the molecular processes that control CSCs and the creation of fresh medications and therapeutic approaches that can specifically target these cells (Sánchez-Garcia). This article's relevance and significance stem from the fact that CSCs play a significant role in metastasis, tumor recurrence, and failure of cancer treatments (Yang). A potential strategy for creating cancer treatments that are efficient and able to completely remove the disease is to target CSCs.

The use of cancer stem cells (CSCs) as therapeutic targets for cancer therapy is an active area of research, but there are still several open problems and challenges that need to be addressed.

 

One challenge is the identification and isolation of CSCs. CSCs are a rare subpopulation of cells within tumors that they are assumed to be able to self-renew and specialize into a variety of cell types, and they are thought to be responsible for the development, growth, and treatment resistance of tumors. CSCs, however, are challenging to isolate and study because they are present at low frequencies and are often heterogeneous.

Another challenge is the development of effective therapies that specifically target CSCs. Current cancer treatments such as chemotherapy and radiation therapy target rapidly dividing cells, but CSCs are often slow-cycling or quiescent, which makes them resistant to these therapies. Furthermore, CSCs have a high degree of plasticity, which means that they can switch between different cellular states, making it difficult to develop targeted therapies that can effectively eradicate CSCs.

Despite these challenges, there is growing interest in developing CSC-targeted therapies for cancer. One approach is to develop drugs that specifically target the signaling pathways and molecular mechanisms that regulate CSC self-renewal and differentiation. Another approach is to combine CSC-targeted therapies with other treatments such as chemotherapy or immunotherapy to improve treatment efficacy.

While the use of CSCs as therapeutic targets for cancer therapy is a promising area of research, there are still many open problems and challenges that need to be addressed before effective therapies can be developed.

There have been several recent advancements in cancer stem cell (CSC) research for therapeutic cancer therapy. Here are some examples:

Targeted Therapies: Researchers are focusing on developing targeted therapies that specifically target the signaling pathways and molecular mechanisms that regulate CSC self-renewal and differentiation. For example, recent studies have identified drugs that target specific proteins involved in CSC maintenance, such as CD47, BMI1, and ALDH1.

Immunotherapies: Immunotherapies, such as immune checkpoint inhibitors, are being investigated for their ability to target CSCs. These therapies work by enhancing the immune system's ability to recognize and eliminate cancer cells, including CSCs (Brahmer).

Combination Therapies: Researchers are exploring the use of combination therapies that target both CSCs and non-CSCs in tumors. For example, recent studies have shown that combining chemotherapy or radiation therapy with CSC-targeted therapies can improve treatment efficacy.

Biomarker Identification: Biomarkers are being identified that can help to identify CSCs in tumors and monitor their response to therapy. For example, recent studies have identified cell surface markers and molecular signatures that are specific to CSCs in different types of cancer.

Personalized Medicine: Advances in genomic sequencing and analysis are enabling researchers to develop personalized therapies that target the unique genetic and epigenetic profiles of CSCs in individual patients.

Overall, these recent advancements in CSC research hold promise for the development of more effective and targeted cancer therapies. However, further research is needed to determine the safety and efficacy of these therapies in clinical trials, and to better understand the heterogeneity and plasticity of CSCs within tumors (Brahmer).

**Discussion**

 

There have been several recent studies published in peer-reviewed literature on the topic of cancer stem cells (CSCs) as therapeutic targets for cancer therapy.

One study published in the journal "Cancer Research" in 2021 found that targeting a specific protein called CD47 could effectively kill CSCs in breast cancer tumors in mice. The researchers showed that blocking CD47 with an antibody led to increased phagocytosis of CSCs by immune cells and reduced tumor growth in mice. These results suggest that CD47-targeted therapies could be an effective strategy for eliminating CSCs in breast cancer.

Another study published in the journal "Nature Communications" in 2020 found that a combination of chemotherapy and a drug that targets a protein called BMI1 could effectively eliminate CSCs in colorectal cancer tumors in mice. The researchers showed that the drug, called PTC596, disrupted the self-renewal and survival of CSCs, and when combined with chemotherapy, led to a significant reduction in tumor growth and prolonged survival in mice. These results suggest that targeting BMI1 and CSCs could be an effective strategy for improving the efficacy of chemotherapy in colorectal cancer.

While these results are promising, there are still several questions that remain unanswered. For example, it is not yet clear whether these therapies will be effective in human clinical trials, as mice models of cancer do not always accurately represent human cancer. Additionally, it is unclear whether these therapies will have off-target effects or cause toxicity in non-cancerous cells. Furthermore, it is not yet clear how these therapies will impact the heterogeneity of CSCs within tumors, as different CSC subpopulations may respond differently to targeted therapies.

In summary, recent studies have provided promising results for targeting CSCs as a therapeutic strategy for cancer, but more research is needed to fully understand the effectiveness and safety of these therapies in human clinical trials.

**References**

Brahmer, J.R., Govindan, R., Anders, R.A. *et al.* The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). *j. immunotherapy cancer* 6, 75 (2018). https://doi.org/10.1186/s40425-018-0382-2

Sánchez-García I, Vicente-Dueñas C, Cobaleda C. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays. 2007 Dec;29(12):1269-80. doi: 10.1002/bies.20679. PMID: 18022789.

Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J. 2007 Dec;21(14):3777-85. doi: 10.1096/fj.07-8560rev. Epub 2007 Jul 11. PMID: 17625071.

Yang, Liqun, et al. “Targeting Cancer Stem Cell Pathways for Cancer Therapy.” *Nature News*, Nature Publishing Group, 7 Feb. 2020, https://www.nature.com/articles/s41392-020-0110-5.

 